Cangming M Yang from 21 Continental Ct, South River, NJ 08882, age 63

Us Patents

Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use
view source
US Patent:

7989472, Aug 2, 2011
Filed:

Mar 19, 2007
Appl. No.:

12/225056
Inventors:

Ronald M. Kim - Summit NJ, US
Emma R. Parmee - Scotch Plains NJ, US
Qiang Tan - Westfield NJ, US
Ashley Rouse Lins - Edison NJ, US
Jiang Chang - Westfield NJ, US
Cangming Yang - Highland Park NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/47
A61K 31/4184
C07D 215/00
C07D 235/04
US Classification:

514311, 546112, 546152, 546174, 546175, 5483027, 5483097, 548469, 548510, 548217, 514299, 514385, 514394
Abstract:

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Pyridyl And Phenyl Substituted Piperazine-Piperidines With Cxcr3 Antagonist Activity
view source
US Patent:

20070021611, Jan 25, 2007
Filed:

Feb 14, 2006
Appl. No.:

11/353697
Inventors:

Brian McGuinness - Plainsboro NJ, US
Stuart Rosenblum - West Orange NJ, US
Joseph Kozlowski - Princeton NJ, US
Gopinadhan Anilkumar - Edison NJ, US
Seong Kim - Livingston NJ, US
Neng-Yang Shih - Warren NJ, US
Paul Zavodny - Mountainside NJ, US
Douglas Hobbs - Yardley PA, US
Guizhen Dong - Dayton NJ, US
Yuefei Shao - Princeton NJ, US
Lisa Zawacki - Yardley PA, US
Cangming Yang - Highland Park NJ, US
Carolyn Carroll - Yardley PA, US
International Classification:

C07D 401/00
US Classification:

544360000
Abstract:

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Substituted Indolo[2,3-A]Pyrrolo[3,4-C]Carbazole Compounds Useful In Treating Kinase Disorders
view source
US Patent:

20070249590, Oct 25, 2007
Filed:

Oct 26, 2006
Appl. No.:

11/586817
Inventors:

Lawrence Wilson - Atlanta GA, US
William Murray - Belle Mead NJ, US
Cangming Yang - Highland Park NJ, US
Bingbing Wang - Flemington NJ, US
International Classification:

A61K 31/551
A61P 11/06
A61P 17/06
A61P 19/00
A61P 19/02
A61P 37/06
A61P 37/08
A61P 43/00
C07D 243/10
C07D 487/22
US Classification:

514219000, 540492000, 540555000
Abstract:

The present invention is directed to substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds of formula (I): and forms thereof and their synthesis and use as protein kinase inhibitors and interactions thereof.

Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use
view source
US Patent:

20090105310, Apr 23, 2009
Filed:

May 11, 2007
Appl. No.:

12/227030
Inventors:

Ronald M. Kim - Summit NJ, US
Emma R. Parmee - Scotch Plains NJ, US
Qiang Tan - Westfield NJ, US
Cangming Yang - Highland Park NJ, US
Ashley Rouse Lins - Edison NJ, US
International Classification:

A61K 31/4402
C07D 471/02
C07C 63/33
C07D 211/76
A61K 31/44
A61P 3/04
C07D 215/18
A61K 31/495
A61K 31/19
US Classification:

514351, 544350, 562492, 546300, 546180, 514249, 514569, 514277
Abstract:

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Novel Prolylcarboxypeptidase Inhibitors
view source
US Patent:

20130040929, Feb 14, 2013
Filed:

May 6, 2011
Appl. No.:

13/642646
Inventors:

Jeffrey J. Hale - Westfield NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Zhi-Cai Shi - Monmouth Junction NJ, US
Min Shu - Green Brook NJ, US
Zhicai Wu - Montvale NJ, US
Cangming Yang - South River NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/506
C07D 401/04
A61K 31/454
A61K 31/4545
A61P 3/00
C07D 413/14
A61K 31/5377
A61K 31/4985
A61P 3/04
A61P 3/10
C07D 401/14
A61K 31/497
US Classification:

51421002, 544331, 514275, 546211, 514326, 546194, 514318, 544328, 514256, 544405, 51425505, 544122, 5142365, 544129, 5142102, 514249
Abstract:

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

Novel Prolylcarboxypeptidase Inhibitors
view source
US Patent:

20130059830, Mar 7, 2013
Filed:

May 16, 2011
Appl. No.:

13/696831
Inventors:

Jinlong Jiang - Scotch Plains NJ, US
Zhi-Cai Shi - Monmouth Junction NJ, US
Min Shu - Green Brook NJ, US
Cangming Yang - South River NJ, US
International Classification:

A61K 31/506
C07D 413/14
A61P 3/00
A61K 31/55
A61P 3/04
A61P 3/10
C07D 401/14
A61K 31/5377
US Classification:

51421002, 544331, 514275, 544122, 5142365, 540601, 51421706, 544295, 51425218, 544296, 514249
Abstract:

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

Antidiabetic Compounds
view source
US Patent:

20160332968, Nov 17, 2016
Filed:

Feb 3, 2015
Appl. No.:

15/110894
Inventors:

Harry CHOBANIAN - Kenilworth NJ, US
Duane DEMONG - Kenilworth NJ, US
Yan Guo - Kenilworth NJ, US
Zhiyong Hu - Kenilworth NJ, US
Barbara PIO - Kenilworth NJ, US
Christopher PLUMMER - Kenilworth NJ, US
Dong XIAO - Kenilworth NJ, US
Cangming YANG - Kenilworth NJ, US
Rui ZHANG - Kenilworth NJ, US
- Rahway NJ, US
- Kenilworth NJ, US
International Classification:

C07D 211/42
C07D 211/22
C07D 205/04
C07D 209/54
C07D 209/52
C07D 207/12
C07D 205/12
C07C 217/52
C07D 401/04
C07D 265/30
C07C 59/72
C07D 213/64
C07D 213/69
C07D 239/52
C07D 231/20
C07D 307/88
C07D 491/056
C07D 307/86
C07D 213/30
C07D 213/647
C07D 207/08
Abstract:

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic Bicyclic Compounds
view source
US Patent:

20160280626, Sep 29, 2016
Filed:

Dec 1, 2014
Appl. No.:

15/034189
Inventors:

- Rahway NJ, US
Harry R. Chobanian - Aberdeen NJ, US
Yan Guo - Westfield NJ, US
Hubert Josien - Jersey City NJ, US
Michael Miller - Scotch Plains NJ, US
Barbara Pio - West Orange NJ, US
Christopher W. Plummer - Hoboken NJ, US
Cangming Yang - South River NJ, US
Dong Xiao - Warren NJ, US
International Classification:

C07C 59/72
C07D 213/64
A61K 31/44
C07D 209/08
A61K 31/404
C07D 231/12
A61K 31/415
C07D 417/04
A61K 31/427
C07D 471/04
A61K 31/437
C07D 249/04
A61K 31/4192
C07D 333/24
A61K 31/381
C07C 255/59
A61K 31/277
C07D 221/04
A61K 31/435
A61K 45/06
A61K 31/192
Abstract:

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.